With RSV cases on the rise, Pfizer has developed new vaccines designed to compliment existing flu and COVID-19 shots, fortifying our immune systems against seasonal threats. Vaccines undergo extensive review across multiple committees and government bodies before public release, and streamlined interfaces are critical in this process. These interfaces enable pharmaceutical and government personnel— from accountants and sales teams to healthcare providers— to efficiently navigate, understand, and educate others on emerging health solutions.